DRUG · Mapped RxNorm record
Pemetrexed
Normalized identity: pemetrexedView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
NCT01836575
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Carboplatin
Normalized identity: carboplatinView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedAlimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non Small Cell Lung Carcinomaunresolved
Interventions
PemetrexedDRUG · verified · RxNorm: pemetrexed
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
Instituto Nacional de Cancer, Brazillead sponsor
Eli Lilly and Companycollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01836575 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.